Analysis of the use for antiviral drugs in the treatment of COVID-19 patients in a Hubei hospital in 2020
10.12206/j.issn.2097-2024.202009044
- VernacularTitle:2020年湖北省某医院救治新冠肺炎患者的抗病毒药物使用分析
- Author:
Suqiu PANG
1
Author Information
1. No. 910 Hospital of Joint Logistics Support Force of the PLA, Quanzhou 362000, China.
- Keywords:
COVID-19;
antiviral drugs;
drug utilization review;
pharmaceutical care
- From:
Journal of Pharmaceutical Practice and Service
2022;40(6):583-586
- CountryChina
- Language:Chinese
-
Abstract:
Objective To retrospectively analyze the use of antiviral drugs in 1765 patients admitted to a hospital of COVID-19 in Hubei Province, and to provide experience and suggestions for clinical rational drug use. Methods The antiviral drugs used in a hospital in Hubei Province during the treatment of COVID-19 patients from February to April 2020 were analyzed according to the "New Coronary Virus Pneumonia Diagnosis and Treatment Program" recommendated by the National Health Commission. Results Among the 1765 patients, 1114 (63.11%) were treated with antiviral drugs. The top three antiviral drugs were arbidol (981 cases, use rate 55.58%), IFN-α-2b (340 cases, use rate 19.26%) and chloroquine (72 cases, use rate 4.08%) . Among all the antiviral regimens, 636 (57.09%) were treated with arbidol alone, followed by arbidol combined IFN-α-2b 164 (14.72%) , arbidol combined IFN-α-2b 98 (8.8%) , and the top three regimens accounted for 80.61% of all antiviral regimens. According to the COVID-19, IFN-α-2b, Arbidol, and chloroquine had more than 20% of the over-treatment duration, 6 patients used more than 3 antiviral drugs, and 50 patients had not been recommended for hydroxychloroquine. Conclusion The antiviral drugs used for the treatment of patients with COVID-19 in this hospital are basically used rationally under the guidance of the "New Coronary Virus Pneumonia Diagnosis and Treatment Program" continuously updated by the National Health Commission at the same time..
